Mankind Pharma enters CAR-T therapy with Belgium deal
pre-market1 source ↓machine-written, see hownot a recommendation
- MANKIND close
- ₹2,276
- On the day
- -3.07%
- Futures OI, short build-up
- +2.8%
- Put-call ratio
- 0.45
- Max pain
- ₹2,400
Mankind Pharma agreed to acquire a 70% stake in Belgium-based Armed Cell Therapeutics B.V. through its Netherlands subsidiary, marking its entry into next-generation CAR-T cancer therapies. The transaction involves an investment of EUR 48 million. Armed Cell Therapeutics is developing armed CAR-T therapies, an approach designed to expand the potential of engineered immune-cell treatments in oncology. 💊
EUR 48 million investment gives Mankind Pharma a controlling position in a specialised biotechnology platform while broadening its long-term innovation pipeline beyond conventional medicines. The agreement is strategic rather than an immediate earnings event: the near-term market focus is likely to remain on transaction completion, funding, development milestones and the progress of the company’s CAR-T pipeline.
OI Charts data showed the stock closed at ₹2,276 on 16 Oct 2026, down 3.1% on the day, with volume of 889,731 shares. The stock had declined 3.9% over five sessions and 1.1% over 20 sessions, while remaining between its 52-week range of ₹1,910 and ₹2,642. The market reaction therefore remained weak despite the announced expansion into a high-growth oncology segment.
In derivatives, futures open interest rose 2.8% to 3,661,000 shares as the price fell, indicating a short build-up. The futures contract traded at a 0.34% premium to the underlying, while the put-call ratio stood at 0.45. For the 27 Oct 2026 expiry, the largest put open interest was at ₹2,500 and the largest call open interest was at ₹2,600. Max pain was ₹2,400, giving traders key reference levels above the latest close.
The next developments to watch are completion of the majority-stake acquisition, disclosures on the remaining Armed Cell pipeline, regulatory progress and any timelines for clinical or commercial milestones. The 27 Oct expiry has 11 days remaining, so changes around ₹2,400, ₹2,500 and ₹2,600 may shape near-term positioning. The transaction also gives the broader pharma sector a listed-company example of Indian capital entering advanced cell-therapy research. ⚕️
Source: Microbioz India, 17 Oct 2026
Not investment advice. For informational purposes only.